Trending Now - Revolutionary Weight Loss Drug Shows Promising Muscle Preservation

WHO:

NBC News - Drugmaker Eli Lilly is developing the weight loss drug retatrutide.

Fox News Health - Gwyneth Paltrow and neuroscientist Andrew Huberman are mentioned in relation to retatrutide.

WHAT:

PR Newswire - Eli Lilly's retatrutide is an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist.

PR Newswire - The TRIUMPH-1 trial showed that retatrutide met primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss across all doses.

PR Newswire - At 104 weeks, participants who continued on retatrutide 12 mg lost an average of 85.0 lbs (30.3%).

PR Newswire - The trial randomized 2,339 participants in a 1:1:1:1 ratio to receive either retatrutide 4 mg, 9 mg, 12 mg, or placebo.

PR Newswire - The most common adverse events among participants treated with retatrutide were nausea (28.6% to 42.4%), diarrhea (25.2% to 34.1%), and vomiting (10.6% to 25.3%).

PR Newswire - Discontinuation rates due to adverse events were 4.1%, 6.9%, and 11.3% for retatrutide 4 mg, 9 mg, and 12 mg, respectively.

NBC News - Eli Lilly's retatrutide is expected to receive FDA approval in the near future, according to NBC’s medical contributor Dr. Natalie Azar.

PR Newswire - The TRIUMPH-1 trial showed that retatrutide resulted in significant improvements in cardiovascular risk factors, including waist circumference, non-HDL cholesterol, triglycerides, systolic blood pressure, and high-sensitivity C-reactive protein (hsCRP).

PR Newswire - Additional results from the TRIUMPH Phase 3 clinical trial program will be shared later this year, including data from TRIUMPH-2 and TRIUMPH-3 trials.

PR Newswire - In the TRIUMPH-1 trial, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks, with 45.3% achieving ≥30% weight loss.

PR Newswire - Participants with a baseline BMI ≥35 who continued on retatrutide 12 mg for 104 weeks lost an average of 85.0 lbs (30.3%).

PR Newswire - At the 4 mg dose, participants lost an average of 47.2 lbs (19.0%) at 80 weeks, with a lower discontinuation rate due to adverse events compared to placebo.

PR Newswire - 65.3% of participants taking retatrutide 12 mg achieved a BMI <30 at 80 weeks, including 37.5% of those who started with class 3 obesity (BMI ≥40).

PR Newswire - The trial randomized 2,339 participants in a 1:1:1:1 ratio to receive either retatrutide 4 mg, 9 mg, 12 mg, or placebo.

NBC News - Retatrutide may be more effective than three popular GLP-1 drugs currently available.

Fox News Health - Retatrutide is described as a triple-agonist GLP-1 therapy that may reduce side effects and help preserve muscle during weight loss.

HOW:

NBC News - The drug is designed to mimic three hormones responsible for hunger regulation and fat burning.

(UPDATED May 22, 2026 01:40 UTC)

Eli Lilly's investigational drug, retatrutide, has shown promising results in the TRIUMPH-1 trial, which demonstrated that it met both primary and key secondary endpoints for obesity, leading to significant weight loss across all doses. Participants who continued on the 12 mg dose lost an average of 85.0 pounds, which is a reduction of 30.3 percent, over a period of 104 weeks. However, the trial also reported common adverse events, including nausea, diarrhea, and vomiting, with discontinuation rates due to these side effects ranging from 4.1 percent to 11.3 percent, depending on the dosage.

(UPDATED May 21, 2026 21:29 UTC)

Eli Lilly's retatrutide is on track to receive FDA approval soon, as reported by NBC’s medical contributor Dr. Natalie Azar. The TRIUMPH-1 trial demonstrated significant improvements in cardiovascular risk factors, including waist circumference and cholesterol levels. Later this year, additional results from the TRIUMPH Phase 3 clinical trial program will be released, featuring data from the TRIUMPH-2 and TRIUMPH-3 trials.

(UPDATED May 21, 2026 17:46 UTC)

In the TRIUMPH-1 trial, participants taking 12 mg of retatrutide experienced significant weight loss, averaging 70.3 pounds, which is about 28.3%, over 80 weeks, with nearly half achieving a weight loss of 30% or more. Those with a baseline BMI of 35 or higher who continued on the 12 mg dose for 104 weeks lost an average of 85 pounds, while participants on the 4 mg dose lost an average of 47.2 pounds at 80 weeks, showing a lower discontinuation rate due to adverse events compared to the placebo group. The trial included 2,339 participants who were randomized to receive either retatrutide at doses of 4 mg, 9 mg, or 12 mg, or a placebo.

(UPDATED May 21, 2026 16:14 UTC)

Eli Lilly is developing a new weight loss drug called retatrutide, which may prove to be more effective than three popular GLP-1 drugs currently on the market. This triple-agonist therapy is designed to mimic three hormones that regulate hunger and fat burning, potentially reducing side effects and helping to preserve muscle during weight loss. Notably, Gwyneth Paltrow and neuroscientist Andrew Huberman have been mentioned in discussions surrounding retatrutide.